BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-640. [PMID: 19217154 DOI: 10.1016/s0140-6736(09)60140-9] [Cited by in Crossref: 438] [Cited by in F6Publishing: 110] [Article Influence: 36.5] [Reference Citation Analysis]
Number Citing Articles
1 Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm 2017;2017:8909834. [PMID: 28659665 DOI: 10.1155/2017/8909834] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
2 Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep 2017;3:230-2. [PMID: 28443318 DOI: 10.1016/j.jdcr.2017.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Nguyen CT, Bloch Y, Składanowska K, Savvides SN, Adamopoulos IE. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol 2019;206:15-22. [PMID: 30196070 DOI: 10.1016/j.clim.2018.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Barr A, Keat A. Spondyloarthritides: evolving therapies. Arthritis Res Ther 2010;12:221. [PMID: 21205283 DOI: 10.1186/ar3178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
5 Przepiera-Będzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Mediators Inflamm 2015;2015:785705. [PMID: 26339141 DOI: 10.1155/2015/785705] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
6 Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int 2018;38:189-201. [PMID: 29285605 DOI: 10.1007/s00296-017-3919-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
7 Adrovic A, Barut K, Sahin S, Kasapcopur O. Juvenile Spondyloarthropathies. Curr Rheumatol Rep 2016;18:55. [PMID: 27402112 DOI: 10.1007/s11926-016-0603-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 de Winter JJ, Paramarta JE, de Jong HM, van de Sande MG, Baeten DL. Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis. RMD Open 2019;5:e000802. [PMID: 30713720 DOI: 10.1136/rmdopen-2018-000802] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
9 Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol 2018;24:4093-103. [PMID: 30271076 DOI: 10.3748/wjg.v24.i36.4093] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
10 Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1733-53. [PMID: 21902296 DOI: 10.2165/11207530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
11 Mori G, D'Amelio P, Faccio R, Brunetti G. Bone-immune cell crosstalk: bone diseases. J Immunol Res 2015;2015:108451. [PMID: 26000310 DOI: 10.1155/2015/108451] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
12 Yang K, Oak ASW, Elewski BE. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol 2021;22:173-92. [PMID: 33301128 DOI: 10.1007/s40257-020-00578-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 2015;15:489. [PMID: 25447326 DOI: 10.1007/s11882-014-0489-6] [Cited by in Crossref: 95] [Cited by in F6Publishing: 67] [Article Influence: 15.8] [Reference Citation Analysis]
14 Patel M, Day A, Warren RB, Menter A. Emerging therapies for the treatment of psoriasis. Dermatol Ther (Heidelb) 2012;2:16. [PMID: 23205338 DOI: 10.1007/s13555-012-0016-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Desmyter A, Spinelli S, Boutton C, Saunders M, Blachetot C, de Haard H, Denecker G, Van Roy M, Cambillau C, Rommelaere H. Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex. Front Immunol 2017;8:884. [PMID: 28871249 DOI: 10.3389/fimmu.2017.00884] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
16 Lories RJ, de Vlam K. Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? Curr Rheumatol Rep 2012;14:375-82. [PMID: 22527951 DOI: 10.1007/s11926-012-0257-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
17 Köhm M, Behrens F. [Diagnosis and therapy of early psoriatic arthritis]. Z Rheumatol 2012;71:46-52. [PMID: 22286355 DOI: 10.1007/s00393-011-0896-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 2019;71:5-32. [PMID: 30499246 DOI: 10.1002/art.40726] [Cited by in Crossref: 135] [Cited by in F6Publishing: 80] [Article Influence: 45.0] [Reference Citation Analysis]
19 Kezic JM, Glant TT, Rosenbaum JT, Rosenzweig HL. Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther 2012;14:R18. [PMID: 22269151 DOI: 10.1186/ar3697] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
20 Steward-Tharp SM, Song YJ, Siegel RM, O'Shea JJ. New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci 2010;1183:123-48. [PMID: 20146712 DOI: 10.1111/j.1749-6632.2009.05124.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
21 Hedrick MN, Lonsdorf AS, Hwang ST, Farber JM. CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 2010;14:911-22. [PMID: 20629596 DOI: 10.1517/14728222.2010.504716] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
22 Astry B, Venkatesha SH, Moudgil KD. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. Cytokine 2015;74:54-61. [PMID: 25595306 DOI: 10.1016/j.cyto.2014.11.020] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
23 Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterol J 2021;9:581-9. [PMID: 34077627 DOI: 10.1002/ueg2.12094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Shankar G, Mascelli MA. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29:615-624. [PMID: 21747388 DOI: 10.1038/nbt.1903] [Cited by in Crossref: 102] [Cited by in F6Publishing: 77] [Article Influence: 11.3] [Reference Citation Analysis]
25 Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology. 2011;140:1838-1846. [PMID: 21530750 DOI: 10.1053/j.gastro.2011.02.014] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
26 Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015;1:e000017. [PMID: 26509050 DOI: 10.1136/rmdopen-2014-000017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 8.3] [Reference Citation Analysis]
27 Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A. Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison. Rheumatol Ther 2017;4:349-62. [PMID: 28762213 DOI: 10.1007/s40744-017-0070-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
28 Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2019;71:2-29. [PMID: 30499259 DOI: 10.1002/acr.23789] [Cited by in Crossref: 104] [Cited by in F6Publishing: 67] [Article Influence: 34.7] [Reference Citation Analysis]
29 Low C, Conway R. Current advances in the treatment of giant cell arteritis: the role of biologics. Ther Adv Musculoskelet Dis 2019;11:1759720X19827222. [PMID: 30800174 DOI: 10.1177/1759720X19827222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
30 Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, Mascelli MA. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011;3:535-45. [PMID: 22123062 DOI: 10.4161/mabs.3.6.17815] [Cited by in Crossref: 131] [Cited by in F6Publishing: 98] [Article Influence: 13.1] [Reference Citation Analysis]
31 St Clair EW. Novel targeted therapies for autoimmunity. Curr Opin Immunol 2009;21:648-57. [PMID: 19828300 DOI: 10.1016/j.coi.2009.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
32 Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010;160:810-20. [PMID: 20590580 DOI: 10.1111/j.1476-5381.2010.00702.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 8.2] [Reference Citation Analysis]
33 Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, Fearon U, Bresnihan B, Tak PP, Gibney RG, Veale DJ, FitzGerald O. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study. Arthritis Res Ther 2011;13:R7. [PMID: 21272347 DOI: 10.1186/ar3228] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
34 Uhlenhake EE, Mehregan DA. Ustekinumab: differential use in psoriasis. Clin Cosmet Investig Dermatol 2011;4:93-9. [PMID: 21760744 DOI: 10.2147/CCID.S17917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
35 Astry B, Harberts E, Moudgil KD. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res. 2011;31:927-940. [PMID: 22149412 DOI: 10.1089/jir.2011.0094] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
36 Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:554-559. [PMID: 19798030 DOI: 10.1038/nrrheum.2009.178] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 9.1] [Reference Citation Analysis]
37 Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci 2018;19:E530. [PMID: 29425183 DOI: 10.3390/ijms19020530] [Cited by in Crossref: 81] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]
38 MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2016;11:CD007572. [PMID: 27885650 DOI: 10.1002/14651858.CD007572.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
39 Iannone F, Santo L, Bucci R, Semeraro A, Carlino G, Paoletti F, Quarta L, Leucci P, Zuccaro C, Marsico A, Scioscia C, D'Onofrio F, Mazzotta D, Muratore M, Cantatore FP, Lapadula G. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol 2018;37:667-75. [PMID: 29411182 DOI: 10.1007/s10067-018-3989-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
40 Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017;12:CD011535. [PMID: 29271481 DOI: 10.1002/14651858.CD011535.pub2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
41 Mercuri SR, Naldi L. Potential role of ustekinumab in the treatment of chronic plaque psoriasis. Biologics 2010;4:119-29. [PMID: 20531968 DOI: 10.2147/btt.s4921] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights 2014;5:9-19. [PMID: 26000152 DOI: 10.1007/s13317-013-0057-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 7.6] [Reference Citation Analysis]
43 Maeda S, Hayami Y, Naniwa T, Ueda R. The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. Int J Rheumatol 2012;2012:539683. [PMID: 22545055 DOI: 10.1155/2012/539683] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
44 Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Arch Immunol Ther Exp (Warsz) 2015;63:435-49. [PMID: 26062902 DOI: 10.1007/s00005-015-0344-z] [Cited by in Crossref: 116] [Cited by in F6Publishing: 93] [Article Influence: 19.3] [Reference Citation Analysis]
45 Song GG, Lee YH. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis. Z Rheumatol 2018;77:613-20. [PMID: 28791450 DOI: 10.1007/s00393-017-0355-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
46 Picchianti-Diamanti A, Rosado MM, D'Amelio R. Infectious Agents and Inflammation: The Role of Microbiota in Autoimmune Arthritis. Front Microbiol 2017;8:2696. [PMID: 29387048 DOI: 10.3389/fmicb.2017.02696] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
47 Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66-82. [PMID: 25729432 DOI: 10.1177/1756283x14558193] [Cited by in Crossref: 89] [Cited by in F6Publishing: 29] [Article Influence: 14.8] [Reference Citation Analysis]
48 van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, Tak PP. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One 2010;5:e12556. [PMID: 20844595 DOI: 10.1371/journal.pone.0012556] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
49 Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf 2019;42:751-68. [PMID: 30739254 DOI: 10.1007/s40264-019-00797-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
50 Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012;2012:819467. [PMID: 22229105 DOI: 10.1155/2012/819467] [Cited by in Crossref: 125] [Cited by in F6Publishing: 110] [Article Influence: 12.5] [Reference Citation Analysis]
51 Kilian A, Chock YP, Huang IJ, Graef ER, Upton LA, Khilnani A, Krupnikova SDS, Almaghlouth I, Cappelli LC, Fernandez-Ruiz R, Frankel BA, Frankovich J, Harrison C, Kumar B, Monga K, Vega JAR, Singh N, Sparks JA, Sullo E, Young KJ, Duarte-Garcia A, Putman M, Johnson S, Grainger R, Wallace ZS, Liew JW, Jayatilleke A. Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum 2020;50:1191-201. [PMID: 32931985 DOI: 10.1016/j.semarthrit.2020.07.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
52 Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123-131. [PMID: 21710141 DOI: 10.1007/s12178-011-9085-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
53 Dobbin-Sears I, Roberts J, O'Rielly DD, Rahman P. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis 2018;9:191-8. [PMID: 30263103 DOI: 10.1177/2040622318781760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Reveille JD. Genetics of spondyloarthritis--beyond the MHC. Nat Rev Rheumatol 2012;8:296-304. [PMID: 22487796 DOI: 10.1038/nrrheum.2012.41] [Cited by in Crossref: 126] [Cited by in F6Publishing: 101] [Article Influence: 14.0] [Reference Citation Analysis]
55 Davari P, Leo MS, Kamangar F, Fazel N. Ustekinumab for the treatment of psoriatic arthritis: an update. Clin Cosmet Investig Dermatol 2014;7:243-9. [PMID: 25214798 DOI: 10.2147/CCID.S50003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
56 Truchetet ME, Mossalayi MD, Boniface K. IL-17 in the rheumatologist's line of sight. Biomed Res Int 2013;2013:295132. [PMID: 23984335 DOI: 10.1155/2013/295132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
57 Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag 2010;6:123-41. [PMID: 20421912 DOI: 10.2147/tcrm.s5599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
58 Gabay C, McInnes IB. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res Ther 2009;11:230. [PMID: 19519923 DOI: 10.1186/ar2680] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
59 Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. Nat Rev Drug Discov 2009;8:355-6. [PMID: 19404310 DOI: 10.1038/nrd2878] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
60 Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, Mitsui H, Suárez-Fariñas M, Krueger JG. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol 2015;67:934-44. [PMID: 25512250 DOI: 10.1002/art.38995] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
61 Laws PM, Young HS. Current and emerging systemic treatment strategies for psoriasis. Drugs 2012;72:1867-80. [PMID: 22938141 DOI: 10.2165/11634980-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
62 Alivernini S, Pugliese D, Tolusso B, Bui L, Petricca L, Guidi L, Mirone L, Rapaccini GL, Federico F, Ferraccioli G, Armuzzi A, Gremese E. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open 2018;4:e000667. [PMID: 29657833 DOI: 10.1136/rmdopen-2018-000667] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
63 Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009;100 Suppl 2:2-13. [PMID: 20096156 DOI: 10.1016/s0001-7310(09)73372-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
64 Bethi S, Dasgupta A, Weisman MH, Learch TJ, Gensler LS, Davis JC, Reveille JD, Ward MM. Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (Hoboken). 2013;65:607-614. [PMID: 23097327 DOI: 10.1002/acr.21878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
65 Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb) 2012;2:1. [PMID: 23205324 DOI: 10.1007/s13555-012-0001-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
66 Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int 2016;36:603-12. [PMID: 26892034 DOI: 10.1007/s00296-016-3436-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
67 Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-210. [PMID: 23569359 DOI: 10.2147/dddt.s32713] [Cited by in Crossref: 61] [Cited by in F6Publishing: 16] [Article Influence: 7.6] [Reference Citation Analysis]
68 Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013;5:277-85. [PMID: 24101949 DOI: 10.1177/1759720X13501021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
69 Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int 2010;30:1547. [PMID: 19888579 DOI: 10.1007/s00296-009-1226-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
70 Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, Balato A. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front Immunol 2018;9:1668. [PMID: 30150978 DOI: 10.3389/fimmu.2018.01668] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 13.3] [Reference Citation Analysis]
71 Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol 2014;66:231-41. [PMID: 24504793 DOI: 10.1002/art.38291] [Cited by in Crossref: 130] [Cited by in F6Publishing: 94] [Article Influence: 18.6] [Reference Citation Analysis]
72 Han G, Li F, Singh TP, Wolf P, Wang XJ. The pro-inflammatory role of TGFβ1: a paradox? Int J Biol Sci 2012;8:228-35. [PMID: 22253566 DOI: 10.7150/ijbs.8.228] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
73 Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martín L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L. Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm 2014;2014:107421. [PMID: 25061259 DOI: 10.1155/2014/107421] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
74 Malaviya AP, Ostör AJ. Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology 2012;20:59-69. [PMID: 22366810 DOI: 10.1007/s10787-012-0123-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
75 Laws PM, Young HS. Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol 2010;3:25-37. [PMID: 21437057 DOI: 10.2147/ccid.s6497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Chimenti MS, Talamonti M, Novelli L, Teoli M, Galluzzo M, Triggianese P, Perricone R. Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature. J Dermatol Case Rep 2015;9:71-5. [PMID: 26512303 DOI: 10.3315/jdcr.2015.1207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
77 Dörner T, Schett G. [80 milestones in rheumatology from 80 years-IV. 2000-2020]. Z Rheumatol 2021;80:528-38. [PMID: 34255165 DOI: 10.1007/s00393-021-01038-8] [Reference Citation Analysis]
78 Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn's disease: can it find its niche? Therap Adv Gastroenterol 2016;9:26-36. [PMID: 26770265 DOI: 10.1177/1756283X15618130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
79 Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol 2017;4:272-7. [PMID: 29308283 DOI: 10.5152/eurjrheum.2017.17037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
80 Ungprasert P, Thongprayoon C, Davis JM 3rd. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis. Clin Rheumatol 2016;35:1795-803. [PMID: 26852316 DOI: 10.1007/s10067-016-3204-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
81 Rahimi H, Ritchlin CT. Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep 2012;14:349-57. [PMID: 22592745 DOI: 10.1007/s11926-012-0259-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
82 Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol 2011;7:588-98. [PMID: 21912431 DOI: 10.1038/nrrheum.2011.125] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
83 Pham PA, Dressler C, Eisert L, Nast A, Werner RN. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Rheumatol Int 2019;39:605-18. [PMID: 30684041 DOI: 10.1007/s00296-019-04244-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
84 Tuskey A, Behm BW. Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease. Clin Exp Gastroenterol. 2014;7:173-179. [PMID: 24904220 DOI: 10.2147/ceg.s39518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
85 Celis R, Planell N, Fernández-Sueiro JL, Sanmartí R, Ramírez J, González-Álvaro I, Pablos JL, Cañete JD. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012;14:R93. [PMID: 22541888 DOI: 10.1186/ar3817] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
86 Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, McMichael A, Kollnberger S. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011;186:2672-80. [PMID: 21248258 DOI: 10.4049/jimmunol.1002653] [Cited by in Crossref: 198] [Cited by in F6Publishing: 172] [Article Influence: 19.8] [Reference Citation Analysis]
87 Mease PJ. Psoriatic arthritis: pharmacotherapy update. Curr Rheumatol Rep 2010;12:272-80. [PMID: 20490726 DOI: 10.1007/s11926-010-0108-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
88 Kim J, Nadella P, Kim DJ, Brodmerkel C, Correa da Rosa J, Krueger JG, Suárez-Fariñas M. Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications. PLoS One 2015;10:e0132454. [PMID: 26176783 DOI: 10.1371/journal.pone.0132454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
89 Komatsu N, Takayanagi H. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol 2012;3:77. [PMID: 22566958 DOI: 10.3389/fimmu.2012.00077] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
90 Cingoz O. Ustekinumab. MAbs 2009;1:216-21. [PMID: 20069753 DOI: 10.4161/mabs.1.3.8593] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
91 Park SJ, Lee YC. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res 2010;11:78. [PMID: 20565710 DOI: 10.1186/1465-9921-11-78] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
92 Jauregui-Amezaga A, Somers M, De Schepper H, Macken E. Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab. Clin Exp Gastroenterol. 2017;10:293-301. [PMID: 29180886 DOI: 10.2147/ceg.s110546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
93 Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135:112-124. [PMID: 22044352 DOI: 10.1111/j.1365-2567.2011.03522.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 14.9] [Reference Citation Analysis]
94 Bakirci Ureyen S, Ivory C, Kalyoncu U, Karsh J, Aydin SZ. What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. Rheumatol Adv Pract 2018;2:rkx019. [PMID: 31431950 DOI: 10.1093/rap/rkx019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
95 de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR. Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs R D 2017;17:29-51. [PMID: 27838901 DOI: 10.1007/s40268-016-0152-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
96 Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A. Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis. BMC Rheumatol 2018;2:3. [PMID: 30886954 DOI: 10.1186/s41927-018-0011-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
97 Wright KT, Giardina C, Vella AT. Therapeutic targeting of the inflammome. Biochem Pharmacol 2014;92:184-91. [PMID: 25204592 DOI: 10.1016/j.bcp.2014.08.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Smith JA. The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis. Curr Rheumatol Rep 2016;18:33. [PMID: 27105640 DOI: 10.1007/s11926-016-0585-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
99 van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep 2011;13:353-9. [PMID: 21503693 DOI: 10.1007/s11926-011-0181-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
100 Toussirot E, Michel F, Béreau M, Binda D. Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. Patient Prefer Adherence 2013;7:369-77. [PMID: 23641151 DOI: 10.2147/PPA.S33162] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
101 Chi CC, Wang SH. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. Biomed Res Int 2014;2014:862851. [PMID: 24605338 DOI: 10.1155/2014/862851] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
102 O'Rielly DD, Rahman P. Advances in the genetics of spondyloarthritis and clinical implications. Curr Rheumatol Rep 2013;15:347. [PMID: 23771560 DOI: 10.1007/s11926-013-0347-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
103 García-Vicuña R, Garrido N, Gómez S, Joven B, Queiro R, Ramírez J, Rebollo F, Loza E, Sellas A. Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process. Rheumatol Int 2021;41:1549-65. [PMID: 33934175 DOI: 10.1007/s00296-021-04877-5] [Reference Citation Analysis]
104 Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74:423-41. [PMID: 24566842 DOI: 10.1007/s40265-014-0191-y] [Cited by in Crossref: 133] [Cited by in F6Publishing: 88] [Article Influence: 22.2] [Reference Citation Analysis]
105 Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-mo and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990-999. [PMID: 24482301 DOI: 10.1136/annrheumdis-2013-204655] [Cited by in Crossref: 405] [Cited by in F6Publishing: 304] [Article Influence: 57.9] [Reference Citation Analysis]
106 Tsukazaki H, Kaito T. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. Int J Mol Sci 2020;21:E6401. [PMID: 32899140 DOI: 10.3390/ijms21176401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
107 Champs B, Degboé Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD Open 2019;5:e000763. [PMID: 30792887 DOI: 10.1136/rmdopen-2018-000763] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
108 Van Praet L, Jacques P, Van den Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol 2012;8:288-95. [PMID: 22508429 DOI: 10.1038/nrrheum.2012.42] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
109 Montepaone M, Lubrano E, Carboni A, Spadaro A. Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatol 2014;6:7-13. [PMID: 27790030 DOI: 10.2147/OARRR.S56048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB; PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6. [PMID: 24553909 DOI: 10.1136/annrheumdis-2013-204741] [Cited by in Crossref: 189] [Cited by in F6Publishing: 139] [Article Influence: 27.0] [Reference Citation Analysis]